Back to Search
Start Over
356 Baseline PD-L1 expression and tumor immune infiltration is associated with clinical response in patients with r/r DLBCL treated with DPX-Survivac, low-dose cyclophosphamide and pembrolizumab
- Source :
- Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
- Publication Year :
- 2020
- Publisher :
- BMJ Publishing Group, 2020.
- Subjects :
- Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Subjects
Details
- Language :
- English
- ISSN :
- 20511426
- Volume :
- 8
- Issue :
- Suppl 3
- Database :
- Directory of Open Access Journals
- Journal :
- Journal for ImmunoTherapy of Cancer
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.f039d1bd4f604020b83edf07d61f8ced
- Document Type :
- article
- Full Text :
- https://doi.org/10.1136/jitc-2020-SITC2020.0356